PolyPeptide Unveils Strong 2025 Preliminary Results With Double-Digit Revenue Growth

LiquidationSurvivor · 2026-02-03T18:02:45+00:00

PolyPeptide Group AG reported strong preliminary financial results for 2025, with revenue up 15.6% to EUR 389 million, driven by demand for metabolic therapeutics. EBITDA margins improved to 11-12%, supported by significant capital investment and solid cash reserves, leading to a positive market response.

LiquidationSurvivor

2026-02-03 18:02:45

Abstract generation in progress

PolyPeptide Group AG (PPGN.SW) has unveiled its preliminary 2025 financial results, demonstrating robust performance with significant increases in both revenue and profitability. The Swiss pharmaceutical company’s strong showing reflects growing market demand for its therapeutic solutions, positioning it favorably for continued expansion.

Revenue Surge Fueled by Metabolic Therapeutics Demand

The company achieved approximately EUR 389 million in revenue for the 2025 financial year, representing a notable 15.6 percent increase from the previous year. This impressive growth was primarily driven by robust demand for metabolic therapeutics, a key focus area for PolyPeptide’s business strategy. The revenue expansion underscores the company’s ability to capitalize on emerging market opportunities and maintain strong customer momentum in an evolving pharmaceutical landscape.

Margin Expansion and Strategic Capital Investment

PolyPeptide demonstrated significant operational improvements, with the EBITDA margin climbing to an estimated 11 to 12 percent, a substantial jump from 7.5 percent in the prior year. This margin expansion reflects improved operational efficiency and better cost management across the organization. Complementing these gains, the company invested just over EUR 100 million in capital expenditures during the year, a level consistent with its strategic development plans and future growth initiatives.

Robust Cash Position and Market Response

The company closed out 2025 with EUR 75 million in cash reserves, supplemented by EUR 51 million available under its revolving credit facility, providing PolyPeptide with substantial financial flexibility. The strong financial position enabled the company to pursue its growth strategy while maintaining operational resilience. Market participants responded positively to the results, with PPGN.SW stock finishing trading on Monday at CHF 31.15, an appreciation of CHF 2.85 or 10.07 percent on the SIX Swiss Exchange, reflecting investor confidence in the company’s trajectory.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.